Pharma API - Companies
-
Upload
adityamenon18 -
Category
Documents
-
view
220 -
download
0
Transcript of Pharma API - Companies
![Page 1: Pharma API - Companies](https://reader031.fdocuments.us/reader031/viewer/2022021119/577d2e961a28ab4e1eaf74c8/html5/thumbnails/1.jpg)
8/7/2019 Pharma API - Companies
http://slidepdf.com/reader/full/pharma-api-companies 1/9
SMS Pharma (Listed)
Location: Hyderabad
The company is spread across different therapeutic segments in addition to
diversifying in to Nutraceuticals, Bio and Inorganic products and mostly recently in
to cytotoxic formulations.
The category-wise share of products for the year ended March 2009 is as follows:
ProductCategory
% of STO
Sales (Rs.Cr)
Intermediates 55.37 149.74
Bulk Drugs 44.63 120.68
Source: Capitaline
They are mainly focused on the following types of APIs:
• Anti Cancer
• Anti Diabetic
• Anti Hypertensive
• Anti Infectives
• Anti Ulcer
Highlights:
• The company’s production focus is steadily shifting towards the lifestyle
diseases segments which are expected to be on the rise in the next 4-5
years.
• 5 manufacturing facilities in and around Hyderabad
• Dedicated oncology facility being developed in Vizag, with capabilities to
produce both APIs and formulations
• Multi-purpose API facility being developed in Vizag to specifically cater to the
CRAMS business
• The company has acquired 17 US DMFs
![Page 2: Pharma API - Companies](https://reader031.fdocuments.us/reader031/viewer/2022021119/577d2e961a28ab4e1eaf74c8/html5/thumbnails/2.jpg)
8/7/2019 Pharma API - Companies
http://slidepdf.com/reader/full/pharma-api-companies 2/9
Key Financials:
Rs. Crore 2009 2008 2007 2006 2005
Net Sales240.9
5207.1
9165.9
8120.3
3104.7
8
PAT 6.3 27.16 20.97 8.51 8.44
Cash Flow From OperatingActivities
20.91 5.21 10.81 5.94 7.19
Cash Flow From Investing Activities -65.95-
101.63
-22.43 -6.21 -18.6
Cash Flow From Financing Activities 42.04 24.75101.6
70.99 8.89
Rate of Growth (%)
ROG-Capital Employed (%) 16.5 22.46102.3
59.17 19.89
ROG-Total Assets (%) 15.8 15.97 81.75 7.77 19.48
Key Ratios
Debt-Equity Ratio 0.54 0.39 0.54 1.24 1.29
Long Term Debt-Equity Ratio 0.32 0.22 0.33 0.79 0.85Current Ratio 1.76 2.26 2.08 1.32 1.26
Turnover Ratios
Fixed Assets Ratio 2.25 2.41 2.16 1.55 1.54
Inventory Ratio 3.99 4.56 5.54 5.1 5.42
Debtors Ratio 5.35 4.46 3.72 3.02 3.19
Interest Cover Ratio 1.83 5.71 5.58 2.97 3.63
ROCE (%) 5.73 15.14 22.72 18.08 16.91RONW (%) 3 13.89 17.59 16.42 19.01
Source:
Capitaline
![Page 3: Pharma API - Companies](https://reader031.fdocuments.us/reader031/viewer/2022021119/577d2e961a28ab4e1eaf74c8/html5/thumbnails/3.jpg)
8/7/2019 Pharma API - Companies
http://slidepdf.com/reader/full/pharma-api-companies 3/9
Neuland Laboratories (Listed)
Location: Hyderabad
Neuland’s API products include:
• Anti-Asthmatics
• Anti-infectives
• Drugs for Cardiovascular diseases
• CNS (including Anti-depressants, Anti- Parkinsons and Anti- Alzheimers)
• Corticosteroids
• Anti-Ulcerants
• Anti-Fungals.
The category-wise share of products for the year ended March 2009 is as follows:
Product Category % of STO SalesBulk Drugs 85.61 267.12
Intermediates 10.86 33.9
Others 1.83 5.7
Excise Duty 1.7 5.31
Source: Capitaline
Highlights:
• The company’s product portfolio includes drugs for segments like CVS and
CNS which are on the rise in developed economies of the world and areexpected to clock high growth rate in the next few years
• Over 35 Active USDMF's and 370 Drug Master Files world wide
• 2 manufacturing units, both of which are USFDA and WHO GMP certified
• Capabilities for custom peptide synthesis and contract research
![Page 4: Pharma API - Companies](https://reader031.fdocuments.us/reader031/viewer/2022021119/577d2e961a28ab4e1eaf74c8/html5/thumbnails/4.jpg)
8/7/2019 Pharma API - Companies
http://slidepdf.com/reader/full/pharma-api-companies 4/9
Key Financials:
Rs. Crore 2009 2008 2007 2006 2005
Net Sales306.7
3217.6
7202.3
6163.0
7153.0
1
PAT 11.79 11.35 9.04 6.24 4.89
Cash Flow From OperatingActivities
21.61 11.94 -1.38 11.91 15.26
Cash Flow From Investing Activities -74.19 -59.1 -28.98 -6.5 -16.78
Cash Flow From Financing Activities 53.99 47.98 31.95 -4.04 1.75
Rate of Growth (%)
ROG-Capital Employed (%) 36.25 47.93 48.28 6 12.91
ROG-Total Assets (%) 33.57 46.68 36.21 14.5 8.79
Key Ratios
Debt-Equity Ratio 2.37 1.69 1.1 0.85 0.9
Long Term Debt-Equity Ratio 1.47 1.03 0.62 0.36 0.34
Current Ratio 1.1 1.24 1.33 1.24 1.21
Turnover Ratios
Fixed Assets Ratio 1.99 2.28 2.57 2.26 2.34
Inventory Ratio 4.97 4.32 4.75 4.31 3.98
Debtors Ratio 5.09 4.8 5.99 7.01 7.77
Interest Cover Ratio 2 2.07 2.32 2.44 2.1
ROCE (%) 12.1 12.22 15.43 16.67 18.14
RONW (%) 16.71 18.12 16.64 12.98 11.06
Source:
Capitaline
![Page 5: Pharma API - Companies](https://reader031.fdocuments.us/reader031/viewer/2022021119/577d2e961a28ab4e1eaf74c8/html5/thumbnails/5.jpg)
8/7/2019 Pharma API - Companies
http://slidepdf.com/reader/full/pharma-api-companies 5/9
Parabolic Drugs (Unlisted)
Location: Chandigarh
Parabolic Drugs has a presence in the API & API Intermediates segment offering a
product basket of Semi Synthetic Penicillin’s (oral & Sterile) and Cephalosporin’s
(oral) and Cephalosporin Sterile.
The category-wise share of products for the year ended March 2009 is as follows:
Product Category % of STO Sales
Semi Synthetic Penicillin 40.96 176.2
Cephlosplorins 32.69 140.65
6 Amino Pencillinic Acid 14.06 60.51
Excise Duty 8.21 35.3
By products 3.95 17.01
Job Work 0.13 0.55
Source:
Capitaline
Highlights:
• Supplier for companies like Ranbaxy, Cipla, Alkem labs and Aristo Pharma
• Export presence in SE Asia, North America, Latin America, Middle East and
some regions of Africa. The company is aggressively targeting the Middle
East markets
• New facility being set up in Barwala, Punjab to focus on CRAMS business
• Synthetic Penicillin and Cephalosporins are significant therapeutic segments
in the Indian Pharma market and have displayed significant growth rates
(~13%) in the last 3 years. Cephalosporins held the largest market share with
7.8% in 2008-09 as per CRISIL research
![Page 6: Pharma API - Companies](https://reader031.fdocuments.us/reader031/viewer/2022021119/577d2e961a28ab4e1eaf74c8/html5/thumbnails/6.jpg)
8/7/2019 Pharma API - Companies
http://slidepdf.com/reader/full/pharma-api-companies 6/9
• BTS India Private Equity Fund, based in Mauritius has invested USD 7 million
in the company in 2008 by way of private placement of shares
Key Financials:
Rs. Crore 2009 2008 2007 2006 2005
Net Sales394.9
1273.2
9149.3
487.28 50.8
PAT 23.93 29.67 13.59 8.22 3.22
Cash Flow From OperatingActivities
-40.37 -27.24 -4.89 -7.92 -1.88
Cash Flow From Investing Activities -56.18 -50.14 -26.43 -12.67 -5.54
Cash Flow From Financing Activities 102.7 81.66 31.43 21.08 9.19
Rate of Growth (%)
ROG-Capital Employed (%) 62.94 106.7 78.82106.5
981.28
ROG-Total Assets (%) 71.93 98.79 96.12 66.18 92.66
Key Ratios
Debt-Equity Ratio 2.07 1.83 1.61 1.97 2.81
Long Term Debt-Equity Ratio 1.43 1.38 1.09 1.13 1.08
Current Ratio 1.85 1.99 1.8 1.62 1.26
Turnover Ratios
Fixed Assets Ratio 4.7 5.26 6.49 7.41 6.71
Inventory Ratio 2.97 3.81 3.91 4.28 4.96
Debtors Ratio 3.66 4.48 5.07 6.28 6.9
Interest Cover Ratio 2.06 3.92 3.75 3.26 3.15
ROCE (%) 19.7 28.84 27.94 30.81 22.98
RONW (%) 26.75 51.28 45.2 50.98 50.55
![Page 7: Pharma API - Companies](https://reader031.fdocuments.us/reader031/viewer/2022021119/577d2e961a28ab4e1eaf74c8/html5/thumbnails/7.jpg)
8/7/2019 Pharma API - Companies
http://slidepdf.com/reader/full/pharma-api-companies 7/9
Source:
Capitaline
USV Limited (Unlisted)
The company’s product offering includes Active Pharmaceutical Ingredients (APIs),
Peptides, Biosimilars, Injectables and Ophthalmics and Solid Orals. They have apresence in 57 countries globally. In India, they are the leaders in the oral anti-
diabetic market.
Their API products cover the following therapeutic segments:
• Anti-diabetic drugs
• CNS Drugs
• Oncology
• CVS
• Anti-malarial
• Nephrology
• Immunomodulator
The category-wise share of products for the year ended March 2007 is as follows:
Product Category % of STO Sales
Tablets & Capsules 54.96 354.42Bulk Drugs & Intermediates 29.93 192.99
Liquids 9.84 63.48
Creams & Ointments 4.1 26.46
Product Dossiers 0.72 4.66
Powder 0.43 2.75
Devices 0.01 0.09 Source: Capitaline
![Page 8: Pharma API - Companies](https://reader031.fdocuments.us/reader031/viewer/2022021119/577d2e961a28ab4e1eaf74c8/html5/thumbnails/8.jpg)
8/7/2019 Pharma API - Companies
http://slidepdf.com/reader/full/pharma-api-companies 8/9
Highlights:
• Diversified portfolio with presence in therapeutic segments with expected
high growth rates
• Capabilities of manufacturing small molecule APIs
• Substantial R&D capabilities; capability of fermentation which is not easily
available in India; facilities for custom peptide synthesis
• Presence in upcoming segment of biologics
• 4 manufacturing plants all of which are cGMP certified
• Portfolio of 83 patent submissions for APIs, Finished Dosages and Biosimilars.
Of these 30 patents have been granted and 53 submissions are pending
approval
Key Financials:
Rs. Crore 2009 2008 2007 2006 2005
Net Sales837.1
4672.8
613.29
539.11
476.01
PAT172.6
2146.2
6140.4
3137.2
111.61
Cash Flow From OperatingActivities
0 0137.5
1136.0
4137.1
4
Cash Flow From Investing Activities 0 0 -86.9 -132.8-
131.36
Cash Flow From Financing Activities 0 0 -22.23 -11.58 -12.82
Rate of Growth (%)
ROG-Capital Employed (%) 2.62 19.95 21.45 29.82 29.65
ROG-Total Assets (%) 18.35 20.76 21.55 29.44 30.11
Key Ratios
Debt-Equity Ratio 0.01 0.01 0.01 0.01 0.02
Long Term Debt-Equity Ratio 0.01 0.01 0.01 0.01 0.02
Current Ratio 2.02 2.19 2.25 2.22 2.69
![Page 9: Pharma API - Companies](https://reader031.fdocuments.us/reader031/viewer/2022021119/577d2e961a28ab4e1eaf74c8/html5/thumbnails/9.jpg)
8/7/2019 Pharma API - Companies
http://slidepdf.com/reader/full/pharma-api-companies 9/9
Turnover Ratios
Fixed Assets Ratio 2.04 1.84 2 2.21 2.55
Inventory Ratio 8.14 7.47 7.9 7.91 8.66
Debtors Ratio 9.3 8.83 9.73 11.95 10.04
Interest Cover Ratio 366.19
560.19
1146.71
643.16
1144.54
ROCE (%) 18.9 20.07 25.69 32.19 38.65
RONW (%) 16.98 17.24 22.67 27.78 29.44
Source:
Capitaline